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Attempts to discover genes that are involved in the pathogenesis of major psychiatric
disorders have been frustrating and often fruitless. Concern is building about the need
to understand the complex ways in which nature and nurture interact to produce mental
illness. We analyze the epigenome in several brain regions from schizophrenic patients
with severe cognitive impairment using high-resolution (450K) DNAmethylation array. We
identified 139 differentially methylated CpG sites included in known and novel candidate
genes sequences as well as in and intergenic sequences which functions remain
unknown. We found that altered DNA methylation is not restricted to a particular region,
but includes others such as CpG shelves and gene bodies, indicating the presence of
different DNA methylation signatures depending on the brain area analyzed. Our findings
suggest that epimutations are not relatables between different tissues or even between
tissues’ regions, highlighting the need to adequately study brain samples to obtain reliable
data concerning the epigenetics of schizophrenia.
Keywords: psychology, cognition, executive function, memory, epigenetics, DNA methylation, schizophrenia,
human brain
INTRODUCTION
Schizophrenia is one of the most complex and enigmatic of all psychiatric disorders, being
characterized by the heterogeneous presence of positive, negative, and cognitive symptoms that
affect all aspects of mental activity. Twin, family, and adoption studies support the idea that
schizophrenia has a strong genetic component, with an estimated heritability as high as ∼80%
(Owen et al., 2002; Brennand et al., 2011). However, genetics alone cannot explain its incidence.
In this way, the absence of consistently reproducible molecular defects, and the evidence for
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long-lasting changes in gene expression patterns after
environmental exposures suggest that epigenetic mechanisms
play a crucial role in psychiatric diseases, since it is well-
established that environmental exposures can modify DNA
methylation patterns (Feil and Fraga, 2011).
However, our knowledge about the effect of epigenetic
modifications on the development of this disease is in its infancy.
To date, five epigenome-wide association studies (EWAS) have
been published that analyze the DNA methylation profile
of schizophrenic patients. Four of these were performed in
peripheral blood samples and one used the frontal cortex of
schizophrenic patients (Mill et al., 2008; Dempster et al., 2011;
Kinoshita et al., 2013; Nishioka et al., 2013; Liu et al., 2014).
These EWAS are comparable to highly successful genome-
wide association studies but gave mixed results (Rakyan et al.,
2011) describing different altered DNA methylation patterns.
This prompted us to pursue this line of study in an attempt
to obtain independent replications of previously reported
epigenetic alterations, but including new clinical and anatomical
variables.
Anatomical structures in normal brain are responsible
for maintaining adequate cognitive functions. For instance,
prefrontal cortex plays a critical role in supporting emotional
behavior as well as sociomoral processing and executive functions
(Barrasso-Catanzaro and Eslinger, 2016). Other structures,
as hippocampus were related to key functions in spatial
(O’Keefe and Dostrovsky, 1971) and episodic memory (Tulving,
2002), and its underlying molecular pathways are still under
research (Mitsumori, 2008). Even more, anatomical changes of
these structures are related to mental disorders. For instance,
schizophrenic patients showed reduced levels of gray matter
volume in anterior cingulate cortex (ACC; Yamasue et al., 2004)
and the connectivity of this structure with other brain regions
could also play a role in first-episode schizophrenia development
(Ohtani et al., 2015) and might be related to negative symptoms
in schizophrenia (Ohtani et al., 2014).
Given that the spectrum of cognitive defects and symptoms
in schizophrenic patients might be associated with defects
in specific brain structures, our study aimed to compare
the methylation profile of the dorsolateral prefrontal cortex
(DLPFC), hippocampus and ACC of healthy controls and
of patients with a diagnosis of schizophrenia with severe
cognitive deficits in the executive function, memory and with
patterns of positive and negative symptoms, respectively, by
using Illumina’s 450K DNA methylation microarray (Infinium
HumanMethylation450 BeadChip). This microarray encompass
485,764 CpGs located along the human genome, and exceeds the
number of CpGs covered by Illumina’s previous EWAS, in which
the analysis was limited to the CpG sites in CpG islands in the
gene promoter region. Although, we previously have described
the methylation status of the major neurotransmitter systems
associated with the pathophysiology of schizophrenia (Alelu-
Paz et al., 2015) to our knowledge, the present study is the
first to perform this genome-wide methylation array in several
brain regions from schizophrenic patients with severe cognitive
impairment, and so is a unique epigenetic analysis of the normal
and schizophrenic human brain.
MATERIALS AND METHODS
Neuropsychological Test Batteries
We administered a comprehensive battery of neurocognitive
tests to all patients in random order. The battery included the
BuschkeMemory Impairment Screen (MIS; Buschke et al., 1999),
the Frontal Assessment Battery (FAB; Rodriguez del Alamo
et al., 2003), the Mini Mental State Examination (MMSE; Lobo
et al., 1999), and the Positive and Negative Syndrome Scale
(PANSS; Kay et al., 1990), all of which have been validated for
the Spanish population. The MIS is a quick (3–4 min), four-
item, delayed free, and cued recall test of memory impairment.
This test uses controlled learning to ensure attention, induce
specific semantic processing and optimize encoding specificity
to improve detection of cognitive impairment (in this test,
scores from 0 to 3 represent high cognitive impairment and
4–5 represent mild cognitive impairment. Mean age ± SD= 6.1
± 2). The FAB is a short cognitive and behavioral six subtests
devised for screening of a global executive dysfunction (scores
from 0 to 10 represent high cognitive impairment and from 10
to 15 represent mild cognitive impairment. Mean age ± SD =
10.3 ± 4.7). The MMSE is a short, standardized form devised
for screening the cognitive mental state (scores from 10 to 20
represent mild cognitive impairment and <10 represent high
cognitive impairment. Mean age ± SD = 25.4 ± 3.4). Finally,
PANSS was conceived as an operationalized, drug-sensitive
instrument that provides balanced representation of positive and
negative symptoms and gauges their relationship to one another
and to global psychopathology.
We assessed each patient’s cognitive status at least twice over a
period of 24 months prior to the death.
Samples
We selected those deceased patients who had presented a severe
impairment in executive function, memory, or positive/negative
symptoms in the neuropsychological evaluations described
above. The samples were obtained using the Atlas of the
Human Brain (Mai et al., 2004), in order to obtain the same
regions in each subject. We included frozen post-mortem
brain samples from the DLPFC, hippocampus, and ACC of
subjects diagnosed with schizophrenia by DSM-IV-TR criteria
and of healthy controls. We obtained the samples after the
corresponding written consents were given by the healthy
subjects, the patients or their relatives. They were included in
the study after obtaining the approval of the corresponding
ethical committees of the different institutions (Department of
Pathology of the Hospital Ramón y Cajal, Madrid, Spain; the
Brain Bank at the University Hospital Alcorcón Foundation,
Madrid, Spain; and the Neurological Brain Bank of Sant Joan
de Déu-Serveis de Salut Mental, Barcelona, Spain). Table 1S
summarizes the characteristics (post-mortem interval, age at
death, psychiatric diagnosis, and sex) of the frozen tissue
sample (see Supplementary Material). We received sections
in dry ice and maintained them at −80◦C until use. In the
study, we included six schizophrenic samples of DLPFC with
a severe executive function deficit, six schizophrenic samples
of hippocampus with severe memory impairment and seven
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schizophrenic samples of ACC with positive and negative
symptoms (two and five samples, respectively). The control
group consisted of three healthy DLPFC, hippocampus, and ACC
samples.
The criteria for including cases in control samples included
a post-mortem delay no longer than 24 h and no clinical or
pathological evidence of neurological or psychiatric disease.
For pathological cases the inclusion criteria included a post-
mortem delay no longer than 24 h, a diagnosis of schizophrenia
(DSM-IV-TR criteria for residual subtype) and an exhaustive
neuropsychological evaluation.
All subjects are high-rate smokers and polymedicated patients
and, therefore, it is not possible to analyze the influence of specific
drug on the DNA methylation patterns.
DNA Extraction
DNA isolation was performed following the protocol established
by Alelu-Paz et al. (2015) for human brain samples.
Identification of Differentially Methylated
CpGs
After bisulfite conversion of 500 ng of each sample, we used
4µl of bisulfite-converted DNA to hybridize on the Infinium
HumanMethylation450 Beadchip, following the Illumina
Infinium HD Methylation protocol. Detailed information
about the contents of this array is available in the Infinium
HumanMethylation450 Beadchip user guide and data sheet. Two
previous papers described the technical schemes, the accuracy
and the high reproducibility of this array (Sandoval et al., 2011;
Kinoshita et al., 2013). To analyze the DNA methylation data
we used the methylation analysis module available within the
BeadStudio program (Illumina, Inc.).
To calculate the DNA methylation status of the CpG
sites, we selected the β-value, which represents the signal
ratio from a methylated probe relative to the sum of the
methylated and unmethylated probes, and takes any value
between 0 (unmethylated) and 1 (completely methylated). To
avoid possible sources of technical bias that might influence
the results, we excluded probes located on the X chromosome
and every β value that had a threshold detection value of
p> 0.01. GenomeStudio normalizes data using internal controls
included in the HumanMethylation 450 BeadChip, and also
normalizes data with respect to internal background probes. To
avoid any potential false positive results due to the restricted
number of samples, we have performed an accurate statistical
analysis, considering CpG methylation differences above a cut-
off increment of 0.2 (20% of methylation) in the β-value unless
specifically indicated otherwise.
Gene Functional Classification and
Protein-Protein Interaction Networks
To identify functions associated with the genes analyzed, we
performed gene ontology (GO) analysis using the Database
for Annotation, Visualization, and Integrated Discovery program
(DAVID v6.7; http://david.abcc.ncifcrf.gov), which is able to
extract biological features andmeaning associated with gene lists,
and which has most commonly been employed in genome-wide
or near-genome-wide studies (Dennis et al., 2003). We used
the STRING database v9.05 (http://string-db.org/; Jensen et al.,
2009) to identify all the direct and indirect interactions between
the proteins coded by the genes obtained in our analysis that
operate in coordination with others to enable different biological
processes. Transcription factor binding sites predictory analysis
were performed by using tools from the UCSC Genome Browser
(https://genome.ucsc.edu/).
RESULTS
After filtering the data as described in the Section Materials
and Methods, 288 probes (0.06%) were discarded and 485,476
probes (99.94%) were used for further analysis. First, we
compared the total number of methylated (β ≥ 0.75) and
unmethylated (β ≤ 0.20) CpG sites in schizophrenic and
healthy samples. In general terms, intragroup analysis showed
that, in all brain structures, there were more methylated than
unmethylated CpGs in the schizophrenic and normal brain
(Z-test; p< 0.01). More interestingly, in the intergroup analysis
we found significantly more methylated CpGs in schizophrenic
DLPFC and hippocampus than in the corresponding healthy
brain structures, while more unmethylated probes were found
in the schizophrenic ACC than in the healthy ACC (Z-test;
p < 0.01; Figure 1A and Table 2S). The corresponding global
hierarchical clustering analysis of the methylation state of probes
with 1β-values of >0.2 (n = 301; p < 0.01, SD < 30%)
shows that differentially methylated CpG positions distinguished
schizophrenic from healthy samples (Figure 1B).
Scatterplots comparing the average DNA methylation levels
of the two groups indicate that although the correlation
was high, the methylation profile of a number of CpGs
sites differed between schizophrenic and healthy DLPFC
(Pearson, R2 = 0.993), hippocampus (R2 = 0.994), and ACC
(R2 = 0.993; Figures 1C–E, respectively). Scatterplots comparing
brain areas (DLPFC vs. Hippocampus, DLPFC vs. ACC, and
Hippocampus vs. ACC) are included in the Supplementary
Material (Figures 1S, 2S).
The main objective of this study was to determine the
DNA methylation changes associated with the spectrum of
cognitive defects and symptoms related to chronic schizophrenia
by comparing the DNA methylation pattern of the brain
structures associated with specific cognitive domains, such as
DLPFC with executive function, hippocampus with memory,
and ACC with positive and negative symptoms. Therefore,
we focused on the differences in the methylation patterns
in each of these structures. To this end we considered
as differentially methylated probes those with a 1β > 0.2
between groups (p < 0.01, SD< 20%). Bonferroni correction
for multiple testing was applied at the <10−7 level. When
we compared schizophrenic and healthy DLPFCs, we found
66 differentially methylated probes corresponding to 37 genes
(Table 3S) with a similar proportion of hypermethylated (35/66)
and hypomethylated (31/66) CpG sites in the schizophrenic
compared with control samples. Table 1 summarizes the 10 most
differentially methylated probes (p < 0.01; β > 0.2) in the three
Frontiers in Psychology | www.frontiersin.org 3 September 2016 | Volume 7 | Article 1496
Alelú-Paz et al. Brain DNA Methylation and Cognitive Impairment
FIGURE 1 | (A) Total number of hyper and hypomethylated CpG sites both in schizophrenic and healthy samples; (B) Hierarchical cluster analysis of 301 probes in
the total samples included in our study with a 0.20-fold change in β-values as the cut-off (SD < 30%; Green, samples with lowest methylation level; Red, samples with
highest methylation level). Cluster analysis discriminated between schizophrenic patients (orange box) and control samples (blue box); (C,D,E) Representative
example of the scatter plot for CpG methylation values (AVGβ) between healthy and schizophrenic samples in the (A) DLPC (R2 = 0.9945); (B) Hippocampus
(R2 = 0.9949); and (C) ACC (R2 = 0.9931).
brain areas analyzed between schizophrenic and healthy samples.
From the CpG content and neighborhood context of the 66
differentially methylated CpGs, 24.05% were in CpG islands,
21.5% in CpG shores, 6.3% in CpG shelves, and 48.1% were
outside coding genes or known transcription regulatory elements
(intergenic-open sea; Figure 2A). From the functional genome
distribution standpoint, 24% of CpGs were located in proximal
promoters (defined as the sum of CpG sites located within 200 or
1500 bp upstream of the described transcription start site, 5′UTR
and exon 1), 3.7% CpG sites were located in 3′UTR and, finally,
34.1 and 37.9% CpGs corresponded to gene body and intergenic-
open sea sequences, respectively (Figure 2B). According to their
associated RNA transcripts, 58.2% corresponded to classic coding
messenger RNA genes, 3.7% were linked to non-coding RNAs,
and 37.97% of CpG sites had no associated annotated transcripts
(Figure 2C). It is important to highlight that we found in this
brain area fewer probes associated with promoter regions and
coding transcripts included in the 450K (more than 15% points;
Sandoval et al., 2011). The GO analysis shows that in the DLPFC
there was a functional enrichment of the selected genes in
biological processes with crucial functions in neurotransmission,
such as nucleotide binding (NUBP1, PDXK, and STK32B) and
cell surface receptor-linked signal transduction (GPR133 and
OR5A1; p = 7.7e-3 for GPR133). The network analysis showed
differently directed first-order protein interactions (Figure 2D);
PRKCE was associated with genes that have different roles in the
pathophysiology of the disease, such as PTK2, a key regulator
of schizophrenia-related genes (Chandrasekaran and Bonchev,
2012), ESR1, an estrogen receptor that is altered in the frontal
cortex of schizophrenic patients (Weickert et al., 2008), YWHAZ,
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TABLE 1 | The 10 most differentially methylated probes after Bonferroni’s correction (p < 10–7; β > 0.2) in the different areas analyzed between
schizophrenic and healthy samples.
Feature ID Chr Gene region Schizophrenic Healthy Difference (mean)
Mean SD Mean SD
DLPFC
Undefined 4 Intergenic 0.65 0.13 0.06 0.04 0.59
NUBP1 16 Body 0.89 0.03 0.46 0.00 0.43
STK32B 4 Body 0.82 0.02 0.41 0.04 0.40
AIG1 6 Body 0.81 0.03 0.42 0.02 0.38
PRKCE 2 Body 0.81 0.02 0.43 0.00 0.38
FAM69C 18 3′UTR 0.49 0.20 0.88 0.00 −0.38
RASA3 13 Body 0.50 0.20 0.90 0.02 −0.40
RASA3 13 Body 0.46 0.20 0.87 0.02 −0.41
Undefined 17 Intergenic 0.50 0.17 0.93 0.04 −0.42
ATP11A 13 3′UTR 0.33 0.14 0.90 0.01 −0.56
HIPPOCAMPUS
Non-defined 14 Intergenic 0.70 0.16 0.15 0.18 0.54
HLA-DQA1 6 Body 0.60 0.13 0.10 0.07 0.49
Non-defined 16 Intergenic 0.78 0.02 0.30 0.03 0.48
HCN2 19 Body 0.59 0.14 0.13 0.12 0.46
Non-defined 6 Intergenic 0.75 0.15 0.29 0.04 0.46
Non-defined 16 Intergenic 0.87 0.13 0.42 0.10 0.44
AJAP1 1 Body 0.16 0.19 0.55 0.20 −0.38
HLA-B 6 3′UTR 0.14 0.05 0.57 0.20 −0.43
Non-defined 2 Intergenic 0.38 0.01 0.87 0.00 −0.49
HLA-DRB5 6 Body 0.36 0.19 0.88 0.05 −0.51
ACC
C4orf50 4 3′UTR 0.75 0.15 0.28 0.20 0.47
Undefined 14 Intergenic 0.64 0.20 0.16 0.19 0.47
GALNT1 18 5′UTR 0.84 0.03 0.45 0.06 0.39
VSX2 14 TSS1500 0.54 0.18 0.16 0.20 0.38
SAPS2 22 Body 0.80 0.09 0.44 0.08 0.35
KCNK7 11 1st Exon 0.42 0.20 0.77 0.04 −0.35
Undefined 14 Intergenic 0.35 0.18 0.71 0.04 −0.35
CSMD2 1 Body 0.25 0.14 0.62 0.20 −0.37
FRK 6 3′UTR 0.39 0.15 0.83 0.03 −0.43
TUBAL3 10 TSS200 0.11 0.18 0.69 0.18 −0.58
Chr, Chromosome. TSS, Transcription start site.
whichmediates signal transduction by binding to phosphoserine-
containing proteins and has been associated with schizophrenia
in a previous network analysis (Lee et al., 2011), and TRPV1,
which plays a role in dopaminergic mechanisms associated with
schizophrenia (Blumensohn et al., 2002). Finally, CTNAP2 was
associated with CNTN2, which is involved in the initial growth
and guidance of axons and is downregulated in the superior
temporal gyrus of schizophrenic patients (Roussos et al., 2012).
Comparing methylation profiles revealed 8 hypermethylated
and 10 hypomethylated CpGs in schizophrenic compared with
healthy hippocampus, corresponding to 10 genes (Table 4S).
In this case, most of the differentially methylated CpG sites
were in CpG shores (36.8%) and CpGs isolated in the genome
(47.3%; Figure 3A). From the functional genome distribution
standpoint, most of the CpGs corresponded to gene body and
intergenic-open sea sequences (47.3 and 38.8%, respectively;
Figure 3B). With respect to their associated RNA transcripts,
57.8% were of classic coding messenger RNA genes, while for
42.1% sites there were no annotated transcripts associated with
the described CpG location (Figure 3C). Again, we found more
than 15% points in probes associated with gene body and coding
RNA (Sandoval et al., 2011). The DAVID program identified
one cluster, characterized by a highly significant enrichment of
genes involved in antigen processing and presentation (p= 3.7e-
5). In the known and predicted protein–protein interactions we
draw attention to the associations of HLA-DRB5 with HLA-A
and HLA-B (Figure 3D), which are both involved in presenting
foreign antigens to the immune system and are associated with
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FIGURE 2 | (A) Functional genomic distribution, (B) CpG content and neighborhood context, and (C) associated RNA transcripts of the 66 differentially methylated
CpGs between schizophrenic and healthy samples in the DLPC; (D) Network analysis using STRING (V9.05) identified different protein-protein associations. Stronger
associations are represented by thicker lines.
schizophrenia (Chao et al., 2008; Childs et al., 2011; Gu et al.,
2013), of HLA-B and LIF with IL6 and IL6R, respectively,
which have both been implicated in schizophrenia, although
controversially in the case of the latter (Sun et al., 2008; Liu
et al., 2010; Singh et al., 2011), of HLB-B with HFE and CALR
(Farokhashtiani et al., 2011; Buretic-Tomljanovic et al., 2012)
and, finally, of LIF with LIFR, which participates in signal
transduction by members of the interleukin (IL)-6 cytokine
family and has recently been associated with persecutory delusion
in the Korean population (Kang et al., 2012).
Finally, we compared schizophrenic ACC with corresponding
healthy samples. The results are summarized in Table 5S and
Figure 4. We found a total of 55 differentially methylated
CpG sites corresponding to 32 genes, 41.9% hypermethylated
(24/55), and 58.1% hypomethylated (31/55) in the schizophrenic
ACC, recapitulating the global hypomethylation observed in
this brain structure. As in the other brain structures analyzed,
the distribution and functional location of the differentially
methylated CpGs was variable (Figures 4A–C). In this brain
area, we found a functional enrichment of the selected genes
in biological processes such as protein kinase activity (FRK,
MAST2, KIAA1804) and signal transduction (SID1, IL12RB1,
HLA-DRB5). STRING analysis highlighted first-order protein
interactions among IL12RB1 and IL12B, IL1B, IL6, and IL12A,
all of which have previously been associated with schizophrenia
(Figure 4D) (Ozbey et al., 2008; Shirts et al., 2008; Fatjo-Vilas
et al., 2012; Yoshida et al., 2012).
For probes indicated in Table 1 located at intergenic regions,
we performed a transcription factor binding site prediction
analysis and we did not find any known or predicted
transcription factor that bind to these sequences. The results are
summarized in Table 6S.
DISCUSSION
Herein, we compared the DNA methylation pattern across the
human genome in several normal and schizophrenic brain areas
that have previously been linked to neuropathological features
of schizophrenia, such as DLPFC, hippocampus, and ACC. For
our analysis we selected those patients with severe cognitive
impairments and symptoms characteristic of the disease that are
related with the aforementioned structures. Although, previous
studies have analyzed the DNA methylation status of different
gene regions in brain and peripheral blood samples (Mill et al.,
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FIGURE 3 | (A) Functional genomic distribution, (B) CpG content and neighborhood context, and (C) associated RNA transcripts of the 18 differentially methylated
CpGs between schizophrenic and healthy samples in the hippocampus; (D) Network analysis (STRING V9.05).
2008; Dempster et al., 2011; Kinoshita et al., 2013; Nishioka et al.,
2013; Alelu-Paz et al., 2015), to our knowledge, our study is
the first high-resolution genome-wide DNAmethylation analysis
carried out in brain samples from patients with a severe cognitive
impairment.
In this study, we analyzed a total of 485,476 cytosine positions
distributed across the human genome, with an average of 17 CpG
sites per gene region. We found that altered DNA methylation
in schizophrenia is not restricted to the CpG island located at
the promoter region, and includes others, such as CpG shelves
and gene bodies. In our analysis, most of the CpG sites obtained
were found to correspond to intergenic-open sea sequences.
Epigenetic changes in these sequences (with previously unknown
functions) have been shown to have crucial involvement in
gene activation and de-activation (Hardison, 2012) and also,
its methylation status might lead to facilitate or inhibit the
binding of transcription factors (Jones, 2012). Therefore, our
study furthers our understanding of the functional elements
encoded in the human genome through an analysis not only
of the gene regions that have traditionally been associated with
gene regulation processes, but also of the intergenic regions
that may potentially play a role in the pathophysiology of
schizophrenia.
We know that methylation at CpG sites located in gene
bodies is fundamental to the regulation of gene transcription
elongation and could be also involved in the regulation of
splicing (Jones, 2012). Although most of the gene bodies
are poor in methylated CpGs, the intragenic regions also
contain CpG islands (CGIs) that, with a few exceptions, are
unmethylated. This is particularly important since as many
as 34% of these CGIs are methylated in the human brain,
suggesting a tissue-specific role for this methylation (Maunakea
et al., 2010). Thus, the changes in the methylation state of
the probes located in intragenic regions observed here could
be highly significant for the development of schizophrenia. In
this regard, we found that LIF (leukemia inhibitory factor),
which is hypomethylated in the hippocampus of samples from
schizophrenic patients, could have an important role in the
cognitive impairment associated with schizophrenic disabilities,
since it induces neuronal cell differentiation and participates
in the deterioration of working memory function (Okahisa
et al., 2010). PRKCE and CNTNAP2 are two other genes
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FIGURE 4 | (A) Functional genomic distribution, (B) CpG content and neighborhood context, and (C) associated RNA transcripts of the 55 differentially methylated
CpGs between schizophrenic and healthy samples in the ACC; (D) Network analysis in the ACC.
that are hypermethylated in the DLPFC of schizophrenic
patients. Both are thought to be potential contributors to
the central nervous system pathology in schizophrenia (Nawa
et al., 2000; Roussos et al., 2012). PRKCE is involved in nerve
growth factor (NFG)-induced neurite outgrowth and neuron
morphological change. CNTNAP2 may play a major role in
the formation of functionally distinct domains critical for
saltatory conduction of nerve impulses inmyelinated nerve fibers
and, therefore, its epigenetic alteration is consistent with the
hypothesis that schizophrenia results from poor or miswired
anatomical or functional connections (Salgado-Pineda et al.,
2007).
In psychiatry, most of the studies have tried to elucidate the
role of DNA methylation changes by using peripheral blood
samples. This choice is usually justified by themounting evidence
from other disorders in which disease-associated epimutations
can be detected across different tissue types (Dempster et al.,
2011; Kinoshita et al., 2013). However, DNA methylation
profile is tissue-specific, and the epigenetic signatures are not
always correlated with those obtained from DNA isolated from
peripheral blood samples (Ladd-Acosta et al., 2007; Davies et al.,
2012). Taking this fact into account, we compared our results
with the previous methylation study carried out in peripheral
blood samples from schizophrenic patients (Kinoshita et al.,
2013) being unable to replicate the DNA methylation changes
they observed in that tissue. By using brain samples, instead
leukocytes, we found a global hypermethylation pattern in all
the structures analyzed in schizophrenic and healthy individuals
in contrast to previous findings from peripheral blood samples
that indicated highly significant hypomethylation in patients
with schizophrenia (Shimabukuro et al., 2007; Melas et al.,
2012). This observation highlights the idea that the epigenetic
signatures differ depending on whether brain or blood samples
are analyzed.
Even more, these signatures differ between brain regions.
In this sense, in our study, only nine differentially methylated
probes (1β > 0.2; p < 0.01, SD < 20%) were present in
at least two of the three areas included, corresponding to
intergenic regions (six probes) and three corresponding to genes
(ATP2A3-Body, AIG1-Body, HLA-DRB5-Body). No probe was
repeated across all three brain areas analyzed, so we can conclude
that the schizophrenic and normal human brain have different
anatomical DNA methylation signatures, which are brain-region
dependent.
Therefore, we wished to highlight the need to study brain
samples to obtain reliable data in regard to the epigenetic
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study of this severe mental illness. The more we understand
the dynamic nature of epigenetic the more we need to take
care of the wise tissue selection and its adequate anatomical
identification. The conjunction of these factors will allow us
to deepen our knowledge in schizophrenia, avoiding data
that add “noise” instead truly information, and leading to
a more exact diagnose, treatment, and patients’ life-quality
improvement.
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